1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Project Orbis Nears 30 Approvals In Oncology; Could China Be Added?

 
• By Ramsey Baghdadi

A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.

Confidentiality issues could be slowing US/China regulatory collaborations. • Source: Nielsen Hobbs

China could be a possible addition to the Project Orbis international parallel review initiative within the US FDA’s Oncology Center of Excellence due to high interest from drug sponsors.

However, those plans may be on indefinite hold given the obvious tensions between the two governments over the exchange of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards